Literature DB >> 15795652

10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs.

Juan A Armijo1, Noelia Vega-Gil, Mehrdad Shushtarian, Javier Adín, José L Herranz.   

Abstract

This study was done to evaluate the association between patient age and the concomitant use of enzyme-inducing antiepileptic drugs (AEDs) and oxcarbazepine (OXC) concentration-to-dose ratio (CDR) by a multivariate analysis. The influence of patient age and concomitant AEDs on the trough steady-state serum concentration of 10-hydroxycarbazepine (OHC) normalized to 1 mg/kg body weight of OXC or concentration-to-dose ratio (OHC-OXC-CDR) was assessed by analysis of covariance. Samples were collected from 106 patients (90% outpatients), aged 1-80, who were receiving OXC either alone (n = 41) or in combination with other AEDs (n = 65). The average OHC-OXC CDR was 0.70 +/- 0.26 (mean +/- SD). Analysis of covariance showed that patient age was influential (P < 0.001) and that there was a difference between the noninducers group (OXC or OXC + lamotrigine, topiramate, or valproate) and the inducers group (OXC + phenobarbital or phenytoin) (P < 0.001). The OHC-OXC CDR increased with age (r = 0.14, P < 0.001) and was approximately 48% lower in children aged 6 or less than in patients over 45, and approximately 32% lower in the inducers group than in patients receiving OXC alone. The correlation between OHC-OXC CDR and the age of the patients concerned with OXC alone was r = 0.48, P < 0.001. In the noninducers group the OHC-OXC CDR was 0.59 +/- 0.24 in patients aged 11 or less (n = 16), and 0.81 +/- 0.23 in patients over 11 years (n = 62). In the inducers group it was 0.25 +/- 0.11 in patients aged 11 or less (n = 3) and 0.57 +/- 0.18 in patients over the age of 11 (n = 25). The OHC-OXC CDR increased with patient age and decreased in the presence of enzyme-inducing AEDs in epileptic patients chronically treated with OXC. These influences may be clinically relevant, and, therefore, patient age and the presence of inducers should be considered in estimating either compliance or the OXC dose needed to achieve a desired OHC concentration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795652     DOI: 10.1097/01.ftd.0000155342.93489.fd

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.

Authors:  Christelle Rodrigues; Catherine Chiron; Elisabeth Rey; Olivier Dulac; Emmanuelle Comets; Gérard Pons; Vincent Jullien
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

2.  Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine.

Authors:  Ali Sigaroudi; Gerd A Kullak-Ublick; Stefan Weiler
Journal:  Eur J Clin Pharmacol       Date:  2015-12-03       Impact factor: 2.953

Review 3.  Management of focal-onset seizures: an update on drug treatment.

Authors:  Svein I Johannessen; Elinor Ben-Menachem
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.

Authors:  Yao Lu; Youxin Fang; Xunyi Wu; Chunlai Ma; Yue Wang; Lan Xu
Journal:  Eur J Clin Pharmacol       Date:  2016-11-29       Impact factor: 2.953

6.  Prospective study on long-term treatment with oxcarbazepine in pediatric epilepsy.

Authors:  Emilio Franzoni; Valentina Gentile; Alessandro Pellicciari; Caterina Garone; Luisa Iero; Stefano Gualandi; Duccio Maria Cordelli; Ilaria Cecconi; Filomena Caterina Moscano; Valentina Marchiani; Alessandra Errani
Journal:  J Neurol       Date:  2009-07-14       Impact factor: 4.849

7.  Analysis of influencing factors on monohydroxylated derivative of oxcarbazepine plasma concentration in children with epilepsy.

Authors:  Nannan Yao; Shan Huang; Aiwen Huang; Hongtao Song
Journal:  Eur J Clin Pharmacol       Date:  2022-08-25       Impact factor: 3.064

Review 8.  Does oxcarbazepine warrant therapeutic drug monitoring? A critical review.

Authors:  Penny Bring; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.

Authors:  Yang Wang; Hua-nian Zhang; Chang-he Niu; Ping Gao; Yu-jun Chen; Jing Peng; Mao-chang Liu; Hua Xu
Journal:  Acta Pharmacol Sin       Date:  2014-09-15       Impact factor: 6.150

Review 10.  Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.